neurothrombectomy

neurothrombectomy

(noor″ō-throm-bek′tŏ-mē, nūr″) [ neuro- + thrombectomy ]
The surgical removal of a blood clot from a blood vessel in the brain. It is used to treat acute ischemic stroke.
References in periodicals archive ?
The neurointerventional devices market encompasses neurothrombectomy devices (suction/aspiration device, clot retriever, and snare device), cerebral angiography and stenting system (carotid stent, and embolic protection system), aneurysm coiling devices (platinum coil, liquid embolic agents, and flow diversion device) and support devices (microcatheter, and microguidewire).
In this report, the global neurovascular devices/interventional neurology market is segmented on the basis of technology (embolization & coiling, carotid artery angioplasty & stenting, supporting techniques, and neurothrombectomy) and product (cerebral balloon angioplasty & stenting systems, aneurysm coiling & embolization devices, support devices, and neurothrombectomy devices).
On the basis of products, the global Neurovascular Devices/Interventional Neurology Market is classified into four major segments, namely, aneurysm coiling & embolization devices, cerebral balloon angioplasty & stenting systems, support devices, and neurothrombectomy devices.
Meanwhile, novel reperfusion strategies such as Cerevast's ClotBust ER Sonolysis Headframe System, CoAxia's NeuroFlo and BrainsGate's Ischemic Stroke System, offer unique non-pharmacological approaches alongside currently-approved neurothrombectomy devices from companies like Concentric Medical, Penumbra and ev3.
The neurothrombectomy devices segment of interventional neurology is expected to have a strong growth in coming years of forecast period.
Recently released results from the CREST trial coupled with the approval of hemodynamic repair devices in the US and expansion of neurothrombectomy devices into international markets will fuel growth.
The neurothrombectomy devices market was valued to be more than USD 60 million in 2012 and is expected to grow at the highest growth rate of over 15% from 2013 to 2019 of the entire interventional neurology market.
Reverse Medical Corporation announced today that it has received US Food and Drug Administration (FDA) conditional approval to begin a neurothrombectomy IDE study for its ReStore[TM] Microcatheter at twenty US centers.
Commenting on this regulatory approval, Reverse Medical's Chief Executive Officer Jeffrey Valko said, "The Reverse Medical ReStore[TM] Microcatheter offers the physician three progressive therapeutic options from one device, aimed to optimize acute ischemic stroke patient outcomes: 1) rapid blood flow restoration, 2) direct infusion into the clot, and 3) neurothrombectomy.
Neurointerventional procedures can be performed through different techniques such as neurothrombectomy procedure, cerebral angiography and stenting technique, and coiling procedure.
On the basis of product, the neurovascular devices market is classified into four major segmentsaneurysm coiling & embolization devices (includes embolic coils, flow diversion devices, and liquid embolic agents), cerebral balloon angioplasty & stenting systems (includes carotid artery stents and embolic protection systems), support devices (includes microcatheters and microguidewires), and neurothrombectomy devices (includes clot retrievers, suction & aspiration devices, and snares).